Document:

EX-10.7

 Exhibit 10.7 

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER 

THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

SECOND AMENDMENT 
 to the

 LICENSE AND COMMERCIALISATION AGREEMENT 

by and between 
 BIOTIE
THERAPIES CORP. 
 Tykistökatu 6 

20520 Turku 
 Finland 

(Hereinafter referred to as “BioTie”) 

and 
 H. LUNDBECK A/S 

Ottiliavej 9 
 DK 2500 Valby 

Denmark 
 (Hereinafter referred to
as “Lundbeck”) 
 (Hereinafter each also referred to as “Party” or together as “Parties”)

  

			
	Whereas:		On 23 May 2007 BioTie and Lundbeck entered into License and Commercialisation Agreement (hereinafter the “Agreement”) regarding the commercialisation of Nalmefene, a specific opioid receptor antagonist developed by
BioTie and its collaborators for the treatment of substance abuse disorders such as alcoholism and obsessive compulsive disorders, including but not limited to pathological gambling.
		
	Whereas:		With this second amendment to the Agreement (hereinafter the “Amendment”) the Parties desire to extend the geographical territory of Lundbeck’s rights under the Agreement to cover also the United States, Canada,
Mexico and their territories and possession (including, but not limited to, the Commonwealth of Puerto Rico), and agree on certain arrangements related thereto.

 NOW THEREFORE, the Parties hereby agree as follows: 

  
 1 (3) 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER 

THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

	1.	GENERAL 

 The Parties acknowledge and agree hereby to include this Amendment to be an
integral part of the Agreement and extend, supplement, vary, change, modify and amend the Agreement as set forth herein. The changes shall become effective only upon payment of the execution fee referred to in Section 4 below. 

 

	2.	AMENDMENTS TO THE AGREEMENT 

 The following six (6) Sections of the Agreement shall
be amended as set forth herein. The amendments below include the complete text of each Section and replace the previous text of the respective Section in its entirety. 
  

	2.1	Section 1.1.3 

 “BioTie In-Licensed Know How and Patent Rights”
– the Know How licensed to BioTie by IVAX Corporation under the agreement summarised in Schedule 1.1.3 (a) and the Know How and Patent Rights licensed to BioTie by the University of Minnesota under the agreement summarised in
Schedule 1.1.3 (b). 
  

	2.2	Section 1.1.63 

 ““Territory” – the world, excluding 

 

	 	•	 	Turkey 

  

	 	•	 	North- and South Korea.” 

  

	2.3	Section 1.1.43 

 ““Major Markets” – Germany, France,
Spain, Italy, Japan, the United Kingdom and the United States.” 
  

	2.4	Section 4.6: Royalties 

 “Subject to Section 4.7, Lundbeck will pay to
BioTie, royalties on a Product by Product basis for all Products sold as set forth below: 
 4.6.1 [*****] of that portion of Lundbeck’s
or its Affiliates’ or Sub-licensees’ total Net Sales of Product, which, during the Year in question, is less than [*****] in the Territory; and 

4.6.2 [*****] of that portion of Lundbeck’s or its Affiliates’ or Sub-licensees’ total Net Sales of Product, which, during the
Year in question, is greater than or equal to [*****] in the Territory. 
  

	2.5	Section 5: Development 

  

			
	5.1.1		BioTie acknowledges that Lundbeck has expressed concerns as to whether it will make good commercial sense to Develop Product for Commercialisation in [*****]. BioTie further acknowledges that (particularly considering the current
limited possibilities for obtaining market exclusivity following launch) it

  
 2 (3) 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER 

THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 will not make good commercial sense to Develop Product for Commercialisation in [*****] and
Lundbeck shall have no obligations in that regard unless and until it would, due to change in the market conditions, intellectual property position or otherwise, make commercial sense for Lundbeck to Develop Product for Commercialisation in [*****].

  

	2.6	Section 5: Development 

 The following sentence shall be deleted from
Section 5.1.2, which otherwise shall remain in its original form: “The planned [*****] may be performed subject to that it is needed by BioTie’s current [*****] in its endeavours to get a marketing approval in [*****].”

  

	3.	AMENDMENT TO THE ANNEXES 

 The following BioTie trademarks shall be added to Annex
1.65.: [*****] and [*****]. 
  

	4.	EXECUTION FEE 

 No later than five (5) days following the signing of this Amendment
Lundbeck shall pay to BioTie a fixed sum of [*****] to BioTie’s bank account in [*****]. 
  

	5.	MISCELLANEOUS 

 All other terms of the Agreement shall remain unchanged and in full force
and effect. This Amendment shall come into force when it has been duly signed by both Parties. 
 In Copenhagen, Denmark and Turku, Finland
on this th day of March 2009. 
  

					
	BIOTIE THERAPIES CORP.				H. LUNDBECK A/S
			
	 /s/ Timo Veromaa
				 /s/ Anders Gersel Pedersen

	Timo Veromaa				Anders Gersel Pedersen
	President & CEO				Executive Vice President

  
 3 (3)EX-10.8

 Exhibit 10.8 

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER 

THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

THIRD AMENDMENT 
 to the

 LICENSE AND COMMERCIALISATION AGREEMENT 

by and between 
 BIOTIE
THERAPIES CORP. 
 Tykistökatu 6 

20520 Turku 
 Finland 

(Hereinafter referred to as “BioTie”) 

and 
 H. LUNDBECK A/S 

Ottiliavej 9 
 OK 2500 Valby 

Denmark 
 (Hereinafter referred to
as “Lundbeck”) 
 (Hereinafter each also referred to as “Party” or together as “Parties”) 

 

			
	Whereas:		On 23 May 2007 BioTie and Lundbeck entered into a License and Commercialisation Agreement (hereinafter the “Agreement”) regarding the commercialisation of Nalmefene, a specific opioid receptor antagonist developed
by BioTie and its collaborators for the treatment of substance abuse disorders such as alcoholism and obsessive compulsive disorders, including but not limited to pathological gambling.
		
	Whereas:		With this third amendment to the Agreement (hereinafter the “Amendment”) the Parties desire to extend the geographical territory of Lundbeck’s rights under the Agreement to cover also the Republic of
Turkey.

 NOW THEREFORE, the Parties hereby agree as follows: 

  
 1 (2) 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER 

THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

	1.	GENERAL 

 The Parties hereby acknowledge and agree to include this Amendment to be an
integral part of the Agreement and extend, supplement, vary, change, modify and amend the Agreement as set forth herein. The change shall become effective only upon payment of the execution fee referred to in Section 3 below. 

 

	2.	AMENDMENTS TO THE AGREEMENT 

 The following Section of the Agreement shall be amended as
set forth herein. The amendment below includes the complete text of the Section and replaces the previous text of the Section in its entirety. 
  

	2.1	Section 1.1.63 

 ““Territory”– the world, excluding 

 

	 	•	 	North- and South Korea.” 

  

	3.	EXECUTION FEE 

 No later than five (5) days following the signing of this Amendment
Lundbeck shall pay to BioTie a fixed sum of [*****] to BioTie’s bank account in [*****]. 
  

	4.	MISCELLANEOUS 

 All other terms of the Agreement (including previous amendments) shall
remain unchanged and in full force and effect. This Amendment shall come into force when it has been duly signed by both Parties. 
 In
Copenhagen, Denmark and Turku, Finland on the dates set forth below. 
  

					
	BIOTIE THERAPIES CORP.				H. LUNDBECK A/S
			
	 /s/ Timo Veromaa
				 /s/ Anders Götzsche

	Timo Veromaa				Anders Götzsche
	President and CEO				EVP, Finance, IT & Communication
	On th day of March 2009				On 3 day of April 2009

  
 2 (2)EX-10.9

 Exhibit 10.9 

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER 

THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

FOURTH AMENDMENT 
 to the

 LICENSE AND COMMERCIALISATION AGREEMENT 

by and between 
 BIOTIE
THERAPIES CORP. 
 Tykistökatu 6 

20520 Turku 
 Finland 

(Hereinafter referred to as “BioTie”) 

and 
 H. LUNDBECK A/S 

Ottiliavej 9 
 DK 2500 Valby 

Denmark 
 (Hereinafter referred to
as “Lundbeck”) 
 (Hereinafter each also referred to as “Party” or together as “Parties”)

  

			
	 Whereas:
		On 23 May 2007 BioTie and Lundbeck entered into a License and Commercialisation Agreement (hereinafter the “Agreement”) regarding the commercialisation of Nalmefene, a specific opioid receptor antagonist developed
by BioTie and its collaborators for the treatment of substance abuse disorders such as alcoholism and obsessive compulsive disorders, including but not limited to pathological gambling.
		
	 Whereas:
		With this fourth amendment to the Agreement (hereinafter the “Amendment”) the Parties desire to remove all territorial restrictions for Lundbeck’s rights under the Agreement.

 NOW THEREFORE, the Parties hereby agree as follows: 

  
 1 (3) 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER 

THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

	1.	GENERAL 

 The Parties hereby acknowledge and agree to include this Amendment to be an
integral part of the Agreement and extend, supplement, vary, change, modify and amend the Agreement as set forth herein. The change shall become effective only upon notification by Lundbeck in writing of its entering into a Co-Promotion and
Distribution Agreement with Whanin Pharmaceutical Co. Ltd. regarding the distribution and sale of the Product in the Republic of Korea, referred to in Section 3 below. 
  

	2.	AMENDMENTS TO THE AGREEMENT 

 The following two (2) Sections of the Agreement shall
be amended as set forth herein. The amendments below include the complete text of the Sections and replace the previous text of the Sections in their entirety. 
  

	2.1	Section 1.1.63 

  

	 	•	 	““Territory” – the world” 

  

	2.2	Section 4.6 Royalties 

 “Subject to Section 4.7, Lundbeck will pay to
BioTie, royalties on a Product by Product basis for all Products sold as set forth below: 
 4.6.1 [*****] of that portion of Lundbeck’s
or its Affiliates’ or Sub-licensees’ total Net Sales of Product, which, during the Year in question, is less than [*****] in the Territory excluding the geographical territories of North and South Korea; and 

4.6.2 [*****] of that portion of Lundbeck’s or its Affiliates’ or Sub-licensees’ total Net Sales of Product, which, during the
Year in question, is greater than or equal to [*****] in the Territory excluding the geographical territories of North and South Korea; 

4.6.3 [*****] of Lundbeck’s or its Affiliates’ or Sub- licensees’ total Net Sales of
Product in the geographical territories of North and South Korea. 
  

	3.	MISCELLANEOUS 

 All other terms of the Agreement (including previous amendments, if still
applicable) shall remain unchanged and in full force and effect. This Amendment is subject to Lundbeck entering into a Co-Promotion and Distribution Agreement with Whanin Pharmaceutical Co. Ltd. regarding the distribution and sale of the Product in
the Republic of Korea and shall enter into force upon Lundbeck notifying BioTie in writing of such agreement. 

  
 2 (3) 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER 

THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 In Copenhagen, Denmark and Turku, Finland on this 14th day of July 2010. 

 

					
	BIOTIE THERAPIES CORP.		 		H. LUNDBECK A/S
			
	 /s/ Timo Veromaa
				 /s/ Ulf Wiinberg

	Timo Veromaa				Ulf Wiinberg
	President & CEO				CEO

  
 3 (3)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}]]